MARKET

DRRX

DRRX

DURECT
NASDAQ
1.210
-0.130
-9.70%
After Hours: 1.210 0 0.00% 19:45 03/28 EDT
OPEN
1.250
PREV CLOSE
1.340
HIGH
1.300
LOW
1.170
VOLUME
234.26K
TURNOVER
0
52 WEEK HIGH
7.46
52 WEEK LOW
0.4703
MARKET CAP
36.09M
P/E (TTM)
-0.7904
1D
5D
1M
3M
1Y
5Y
HC Wainwright & Co. Reiterates Neutral on Durect
Benzinga · 18h ago
H.C. Wainwright Keeps Their Hold Rating on Durect (DRRX)
TipRanks · 20h ago
DRRX Stock Earnings: Durect Beats EPS, Beats Revenue for Q4 2023
Durect reported earnings per share of -10 cents. The company reported revenue of $2.67 million. This was 7.62% better than the analyst estimate for the company to report revenue of -7.5 million. Durect also reported better than expected quarterly earnings.
Investorplace · 1d ago
Durect (DRRX) Reports Q4 Loss, Misses Revenue Estimates
NASDAQ · 1d ago
DURECT Corp reports results for the quarter ended in December - Earnings Summary
DURECT Corp reports results for the quarter ended in December. The company reported a quarterly adjusted loss of 10 cents per share. Revenue fell 19.5% to $2.67 million from a year ago. DURECT shares had risen by 115.3% this quarter.
Reuters · 1d ago
DURECT Corp. Q4 Loss decreases, beats estimates
NASDAQ · 1d ago
Durect: Q4 Earnings Insights
Durect reports its Q4 earnings on March 27. The company beat estimates by 70.0%. Revenue was down $646 thousand from the same period last year. Durect is expected to report its earnings on Wednesday, March 27 at 4:00 p.m.
Benzinga · 1d ago
Durect Q4 2023 GAAP EPS $(0.10) Beats $(0.33) Estimate, Sales $2.669M Beat $2.477M Estimate
Durect reported quarterly losses of $0.10 per share and sales of $2.669 million. The company beat the analyst consensus estimate by 69.7 percent. Durect's sales for the quarter were down 19.49 percent from the same period last year.
Benzinga · 1d ago
More
About DRRX
Durect Corporation is a biopharmaceutical company that is focused on advancing lifesaving investigational therapies. The Company's product candidates include DUR-928 oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. The Company’s other commercial product candidates include POSIMIR, PERSERIS and Methydur Sustained Release Capsules. The Company is conducting a Phase IIb study (AHFIRM) of larsucosterol (DUR-928) in subjects with alcohol-associated hepatitis (Alcoholic Hepatitis (AH) to evaluate the safety and efficacy of larsucosterol treatment. Larsucosterol (DUR-928) is lead product candidate, an endogenous sulfated oxysterol and an epigenetic regulator. The Company focuses on drug delivery technology around its SABER and CLOUD Bioerodible Injectable Depot Systems. SABER uses a high viscosity base component, such as sucrose acetate isobutyrate (SAIB), to provide controlled release of a drug. CLOUD is a class of bioerodible injectable depot technology.

Webull offers DURECT Corp stock information, including NASDAQ: DRRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DRRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading DRRX stock methods without spending real money on the virtual paper trading platform.